NCT01920087View on ClinicalTrials.gov

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

July 31, 2016

Conditions
Atypical Facial PainPersistent Idiopathic Facial PainAtypical Trigeminal NeuralgiaNeuropathic Orofacial PainNeuropathic Facial Pain
Interventions
DRUG

ATNC05

Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

DRUG

Placebo

Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

Trial Locations (1)

33181

Annette C. Toledano MD, North Miami

Sponsors
All Listed Sponsors
lead

Allodynic Therapeutics, Inc

INDUSTRY

NCT01920087 - Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain | Biotech Hunter | Biotech Hunter